Biogen Idec signs development-stage cancer deal with Aveo
This article was originally published in Scrip
Executive Summary
Biogen Idec has acquired development and commercialisation rights to Aveo Pharmaceuticals' discovery-stage ErbB3 programme for the potential treatment of cancer and other diseases.